Brian Mendelsohn
Executive Director, ADCs Exelixis, Inc.
Dr. Brian A. Mendelsohn significantly contributed to ADC technology at Seattle Genetics (2000-2005), synthesizing the first MMAE drug molecule. He completed his Ph.D. in chemistry at the University of British Columbia in 2005, focusing on natural product toxin synthesis. He then established and led the ADC Chemistry group at Agensys (2011-2017), served as Director at Ajinomoto Bio-Pharma Services (2018-2020), and is currently Executive Director of ADCs at Exelixis, Inc. He received the ACS Heroes of Chemistry Award (2018) and the George R. Pettit Award (2024).
Seminars
Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC
- XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
- Laying out demonstration of in vitro bystander and ICD activity
- Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC
- XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
- Laying out demonstration of in vitro bystander and ICD activity
- Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
